Last updated: July 27, 2026
Forest Laboratories LLC v. Apotex Inc. (1:15-cv-00274): Litigation Summary, Key Patent Issues, and Generic Entry Risks
Forest Laboratories LLC brought patent-infringement litigation against Apotex Inc. under the U.S. Hatch-Waxman framework in 1:15-cv-00274. The case centers on Forest’s Orange Book-listed intellectual property for its NDA product and Apotex’s proposed generic, with the outcome shaping launch timing through injunction exposure, settlement leverage, and patent validity/infringement positions.
No case-specific patent numbers, asserted claims, FDA submission details, settlement terms, judgment dates, or docket outcomes are provided in the prompt. Without those facts, a litigation-accurate summary and analysis cannot be produced.
What patents were asserted in Forest Laboratories LLC v. Apotex Inc. 1:15-cv-00274?
Answer (required for accuracy): Not available from the provided information.
Which Orange Book-listed patents drive the case?
Not available from the provided information.
What claim types were at issue (composition, method of use, formulation, polymorphs)?
Not available from the provided information.
Who were the patent holders and assignees on the asserted patents?
Not available from the provided information.
What was Apotex’s generic product and FDA filing status in 1:15-cv-00274?
Answer (required for accuracy): Not available from the provided information.
Was it an ANDA with Paragraph IV certifications?
Not available from the provided information.
What strength and dosage form were targeted?
Not available from the provided information.
What exclusivity or forfeiture theory was raised (if any)?
Not available from the provided information.
What did the complaints and answers allege in Forest v. Apotex 1:15-cv-00274?
Answer (required for accuracy): Not available from the provided information.
Infringement theory
Not available from the provided information.
Non-infringement and invalidity positions
Not available from the provided information.
Contributory or induced infringement allegations
Not available from the provided information.
When did the case move procedurally (motions, claim construction, trial, or dismissal) in 1:15-cv-00274?
Answer (required for accuracy): Not available from the provided information.
Key procedural milestones
Not available from the provided information.
Markman or claim construction schedule
Not available from the provided information.
Interim rulings affecting launch risk
Not available from the provided information.
How did the court rule on validity and infringement in Forest Laboratories LLC v. Apotex Inc. 1:15-cv-00274?
Answer (required for accuracy): Not available from the provided information.
Final judgment outcome
Not available from the provided information.
Patent-by-patent outcomes
Not available from the provided information.
Injunction scope and duration
Not available from the provided information.
Was there a settlement in Forest v. Apotex 1:15-cv-00274, and what did it cover?
Answer (required for accuracy): Not available from the provided information.
Do settlements include licensed launch dates or royalty terms?
Not available from the provided information.
Was there a consent judgment or stipulated dismissal?
Not available from the provided information.
Any agreed design-around or product-labeling constraints?
Not available from the provided information.
What Paragraph IV challenges and FDA timing risks were implicated by the litigation?
Answer (required for accuracy): Not available from the provided information.
Does the case impact 30-month stay eligibility or forfeiture?
Not available from the provided information.
What would be the generic entry window under the litigated patents?
Not available from the provided information.
How many additional Orange Book patents remain beyond the asserted ones?
Not available from the provided information.
How strong was Forest’s patent estate versus Apotex’s likely defenses in 1:15-cv-00274?
Answer (required for accuracy): Not available from the provided information.
Strength drivers (prior art, prosecution history, claim scope)
Not available from the provided information.
Common invalidity themes likely raised (anticipation, obviousness, indefiniteness, written description)
Not available from the provided information.
Likelihood of design-around based on claim structure
Not available from the provided information.
How does this case compare with other Forest Laboratories v. generic defendants in 2015–2016 Hatch-Waxman litigation?
Answer (required for accuracy): Not available from the provided information.
Patterns in settlements, injunction practice, or court outcomes
Not available from the provided information.
Differences by asserted patent family or jurisdiction
Not available from the provided information.
What is the current status of 1:15-cv-00274 and how does it affect commercial launch risk?
Answer (required for accuracy): Not available from the provided information.
Current docket posture (active, stayed, dismissed, or resolved)
Not available from the provided information.
Remaining appeals or related cases
Not available from the provided information.
Key Takeaways
- Forest Laboratories LLC v. Apotex Inc. is identified as 1:15-cv-00274, but the prompt does not include asserted patents, FDA filing details, docket milestones, or judgment/settlement status.
- A litigation summary that is fit for litigation, licensing, or investment decisions requires case-specific facts that are not present.
FAQs
-
What Orange Book patents were listed as being infringed in 1:15-cv-00274?
Not available from the provided information.
-
Did Apotex’s ANDA include Paragraph IV certifications in Forest v. Apotex 1:15-cv-00274?
Not available from the provided information.
-
What claims (composition, method of use, formulation) were asserted?
Not available from the provided information.
-
What was the procedural end point (judgment, settlement, dismissal) of 1:15-cv-00274?
Not available from the provided information.
-
How did the case affect the potential 30-month stay and launch timing for Apotex?
Not available from the provided information.
References (APA)
- Not available from the provided information.
